human multiple myeloma cell line mm 1 (ATCC)
ATCC is a verified supplier 
ATCC manufactures this product 
97
Structured Review
ATCC
human multiple myeloma cell line mm 1
Human Multiple Myeloma Cell Line Mm 1, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 973 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+lines+human+multiple+myeloma+cell+line+mm+1/MM%2E1S/pmc12516852-61-0-28
Average 97 stars, based on 973 article reviews
Human Multiple Myeloma Cell Line Mm 1, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 973 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cell+lines+human+multiple+myeloma+cell+line+mm+1/MM%2E1S/pmc12516852-61-0-28
Average 97 stars, based on 973 article reviews
human multiple myeloma cell line mm 1 - by Bioz Stars,
2026-10
97/100 stars
Images
Related Articles
Cell Culture:Article Title: Protocol to generate allorejection-resistant universal CAR-NKT cells and evaluate their efficacy, mechanism of action, safety, and immunogenicity. Article Snippet: Universal chimeric antigen receptor-engineered invariant natural killer T (CAR-NKT) cells overcome the limitations of allogeneic chimeric antigen receptor (CAR)-T cell therapies, such as graft-versus-host disease and allorejection.. Here, we present a protocol for generating CARNKT cells from hematopoietic stem and progenitor cells (HSPCs), followed by feeder-free ex vivo differentiation.. We also outline assays to assess antitumor efficacy, safety, and allorejection resistance. Magnetic Cell Separation:Article Title: Protocol to generate allorejection-resistant universal CAR-NKT cells and evaluate their efficacy, mechanism of action, safety, and immunogenicity. Article Snippet: Universal chimeric antigen receptor-engineered invariant natural killer T (CAR-NKT) cells overcome the limitations of allogeneic chimeric antigen receptor (CAR)-T cell therapies, such as graft-versus-host disease and allorejection.. Here, we present a protocol for generating CARNKT cells from hematopoietic stem and progenitor cells (HSPCs), followed by feeder-free ex vivo differentiation.. We also outline assays to assess antitumor efficacy, safety, and allorejection resistance. Saline:Article Title: Protocol to generate allorejection-resistant universal CAR-NKT cells and evaluate their efficacy, mechanism of action, safety, and immunogenicity. Article Snippet: Universal chimeric antigen receptor-engineered invariant natural killer T (CAR-NKT) cells overcome the limitations of allogeneic chimeric antigen receptor (CAR)-T cell therapies, such as graft-versus-host disease and allorejection.. Here, we present a protocol for generating CARNKT cells from hematopoietic stem and progenitor cells (HSPCs), followed by feeder-free ex vivo differentiation.. We also outline assays to assess antitumor efficacy, safety, and allorejection resistance. Staining:Article Title: Protocol to generate allorejection-resistant universal CAR-NKT cells and evaluate their efficacy, mechanism of action, safety, and immunogenicity. Article Snippet: Universal chimeric antigen receptor-engineered invariant natural killer T (CAR-NKT) cells overcome the limitations of allogeneic chimeric antigen receptor (CAR)-T cell therapies, such as graft-versus-host disease and allorejection.. Here, we present a protocol for generating CARNKT cells from hematopoietic stem and progenitor cells (HSPCs), followed by feeder-free ex vivo differentiation.. We also outline assays to assess antitumor efficacy, safety, and allorejection resistance. Transfection:Article Title: Protocol to generate allorejection-resistant universal CAR-NKT cells and evaluate their efficacy, mechanism of action, safety, and immunogenicity. Article Snippet: Universal chimeric antigen receptor-engineered invariant natural killer T (CAR-NKT) cells overcome the limitations of allogeneic chimeric antigen receptor (CAR)-T cell therapies, such as graft-versus-host disease and allorejection.. Here, we present a protocol for generating CARNKT cells from hematopoietic stem and progenitor cells (HSPCs), followed by feeder-free ex vivo differentiation.. We also outline assays to assess antitumor efficacy, safety, and allorejection resistance. Recombinant:Article Title: Protocol to generate allorejection-resistant universal CAR-NKT cells and evaluate their efficacy, mechanism of action, safety, and immunogenicity. Article Snippet: Universal chimeric antigen receptor-engineered invariant natural killer T (CAR-NKT) cells overcome the limitations of allogeneic chimeric antigen receptor (CAR)-T cell therapies, such as graft-versus-host disease and allorejection.. Here, we present a protocol for generating CARNKT cells from hematopoietic stem and progenitor cells (HSPCs), followed by feeder-free ex vivo differentiation.. We also outline assays to assess antitumor efficacy, safety, and allorejection resistance. Software:Article Title: Protocol to generate allorejection-resistant universal CAR-NKT cells and evaluate their efficacy, mechanism of action, safety, and immunogenicity. Article Snippet: Universal chimeric antigen receptor-engineered invariant natural killer T (CAR-NKT) cells overcome the limitations of allogeneic chimeric antigen receptor (CAR)-T cell therapies, such as graft-versus-host disease and allorejection.. Here, we present a protocol for generating CARNKT cells from hematopoietic stem and progenitor cells (HSPCs), followed by feeder-free ex vivo differentiation.. We also outline assays to assess antitumor efficacy, safety, and allorejection resistance. Imaging:Article Title: Protocol to generate allorejection-resistant universal CAR-NKT cells and evaluate their efficacy, mechanism of action, safety, and immunogenicity. Article Snippet: Universal chimeric antigen receptor-engineered invariant natural killer T (CAR-NKT) cells overcome the limitations of allogeneic chimeric antigen receptor (CAR)-T cell therapies, such as graft-versus-host disease and allorejection.. Here, we present a protocol for generating CARNKT cells from hematopoietic stem and progenitor cells (HSPCs), followed by feeder-free ex vivo differentiation.. We also outline assays to assess antitumor efficacy, safety, and allorejection resistance. |